Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis-Reference-Cited by-同舟云学术

Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis

Published:2016-11-01 Issue:1 Volume:20 Page:28-35
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Benzon B,Zhao S G,Haffner M C,Takhar M,Erho N,Yousefi K,Hurley P,Bishop J L,Tosoian J,Ghabili K,Alshalalfa M,Glavaris S,Simons B W,Tran P,Davicioni E,Karnes R J,Boudadi K,Antonarakis E S,Schaeffer E M,Drake C G,Feng F,Ross A E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/pcan201649.pdf

Reference35 articles.

1. Thompson RH, Kwon ED, Allison JP . Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy 2009; 1: 129–139.

2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.

3. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269–274.

4. Luo L, Zhu G, Xu H, Yao S, Zhou G, Zhu Y et al. B7-H3 Promotes pathogenesis of autoimmune disease and inflammation by regulating the activity of different T cell subsets. PLoS ONE 2015; 10: e0130126.

5. Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G et al. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res 2015; 3: 849–854.

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UQCRB and LBH are correlated with Gleason score progression in prostate cancer: Spatial transcriptomics and experimental validation;Computational and Structural Biotechnology Journal;2024-12

2. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

3. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies;Cancer Research Communications;2024-05-30

4. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway;BMC Cancer;2024-05-27

5. Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors;Cancer Urology;2024-05-17